🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. IPN10200 placebo, DYSPORT 300 UNITES SPEYWOOD, poudre pour solution injectable, IPN10200

    Ipsen

    Treatment of Moderate to Severe Upper Facial Lines

    phase 2 small molecule active

    1 trial

  2. IPN10200 placebo, Powder for solution for injection, DYSPORT 500 UNITES SPEYWOOD, poudre pour solution injectable

    Ipsen

    Upper limb spasticity after stroke or traumatic brain injury

    phase 2 small molecule active

    1 trial

  3. IPN10200, IPN10200 placebo

    Ipsen

    Episodic Migraine Chronic Migraine

    phase 2 small molecule active

    1 trial

  4. IPTACOPAN, Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023)

    Novartis Pharmaceuticals

    active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis

    phase 2 small molecule active

    1 trial

  5. ISIS 301012 or Placebo

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    2 trials

  6. ISIS 301012 or Placebo

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia, Familial

    phase 2 small molecule completed

    1 trial

  7. ISIS CRP Rx or Placebo

    IONIS PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  8. Ilofotase alfa, Ilofotase alfa Placebo Drug Product

    Lacuna Pharma Pty Ltd

    Risk for renal damage following open heart surgery

    phase 2 small molecule active

    1 trial

  9. Itacitinib, placebo of itacitinib 100mg

    Pari Pharma GmbH

    Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening

    phase 2 small molecule active

    1 trial

  10. Itepekimab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Bronchiectasis

    phase 2 small molecule active

    1 trial

  11. JNJ-81241459, JNJ-81241459 200mg, placebo tablet, JNJ-81241459, JNJ-81241459 50mg, placebo tablet

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  12. JNJ-88545223, JNJ-88545223, JNJ-88545223 Placebo

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  13. JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  14. JTT-861, Placebo tablet for JTT-861

    Lacuna Pharma Pty Ltd

    Heart Failure (Heart Failure with Reduced Ejection Fraction)

    phase 2 small molecule active

    1 trial

  15. Jakavi 15 mg tablets, Placebo of Jakavi 15mg

    Pari Pharma GmbH

    Inclusion body Myositis

    phase 2 small molecule active

    1 trial

  16. KT-621, KT-621, KT-621, The placebo is used in the Double-blind, Placebo-controlled (DBPC) Treatment Period. Participants are randomly assigned to receive either KT-621 or a matching placebo. The placebo is designed to match the study drug in appearance and administration method to maintain blinding.

    Kymera Therapeutics

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  17. KT-621, Placebo oral tablet matched to KT-621, KT-621, KT-621

    Kymera Therapeutics

    Uncontrolled Moderate to Severe Eosinophilic Asthma

    phase 2 small molecule active

    1 trial

  18. Kenacort-A 40, suspensie voor injectie 40 mg/ml, JNJ-81201887, Placebo to match Prednisone 20mg, 5mg, JNJ-81201887, Prednison acis 20 mg, Tabletten, Prednison acis 5 mg, Tabletten

    Janssen-Cilag International N.V.

    Geographic Atrophy

    phase 2 small molecule active

    1 trial

  19. Kerendia 10 mg film coated tablets, Kerendia 20 mg film-coated tablets, Finerenone/Kerendia 10mg and 20mg Placebo equal to test product except active substance, Empagliflozin/Jardiance 10mg Placebo equal to test product except active substance, Jardiance 10 mg film-coated tablets

    Bayer AG

    Chronic kidney disease in type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  20. LISINOPRIL , XXB750, AZILSARTAN MEDOXOMIL , CANDESARTAN , BENAZEPRIL , TRANDOLAPRIL , FOSINOPRIL , PERINDOPRIL , MOEXIPRIL , QUINAPRIL , CAPTOPRIL , EPROSARTAN , RAMIPRIL , IRBESARTAN , VALSARTAN AND SACUBITRIL , ZOFENOPRIL , CILAZAPRIL , DELAPRIL , OLMESARTAN MEDOXOMIL , IMIDAPRIL , 0 mg/1 mL Placebo to XXB750 150 mg/1 mL concentrate for solution for injection, ENALAPRIL , TELMISARTAN , VALSARTAN , LOSARTAN

    Novartis Pharmaceuticals

    Heart Failure

    phase 2 small molecule active

    1 trial

  21. LOU064, -, -, Placebo to LOU064 Film-coated tablet

    Novartis Pharmaceuticals

    Chronic Inducible urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  22. LTI-03, The placebo is InhaLac® 500 (micronized lactose monohyrdate).

    Shanghai Reinovax Biologics Co.,LTD

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  23. LTP001, Placebo to LTP001 1mg and 5mg hard gelatin capsules, LTP001

    Novartis Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  24. La composición cualitativa y cuantitativa de cada sobre de placebo es la siguiente: Bicarbonato sódico 563,75 mg Diluyente/generador de efervescencia Ph Eur Ácido cítrico 410,0 mg Diluyente/generador de efervescencia Ph Eur Maltodextrina 651,25 mg Diluyente Ph Eur Sílice coloidal anhidra 10,0 mg Fluidificante/desecante interno Ph Eur Manitol 769,0 mg Diluyente Ph Eur Sacarina sódica 24,0 mg Edulcorante Ph Eur Aroma de naranja 72,0 mg Saborizante Espec.. interna Masa nominal 2.500 mg El polvo efervescente se

    The George Institute

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources